Carbidopa/levodopa oral solution - Dr. Reddy's Laboratories
Alternative Names: EXN-32Latest Information Update: 26 Dec 2022
At a glance
- Originator Dr Reddys Laboratories
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 26 Dec 2022 No development reported - Phase-II for Parkinson's disease in Italy (PO)
- 04 Nov 2020 Dr. Reddy's Laboratories completes a phase II trial in Parkinson's disease in Italy (PO,Liquid) before November 2020 (EudraCT2017-000262-30)